ArticlePediatric rheumatology online journal2025
A comprehensive report of disease complications of juvenile idiopathic arthritis using a prospective cohort study.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the chronic inflammatory nature of juvenile idiopathic arthritis (JIA), disease complications may occur including chronic joint damage, ocular complications, and growth restrictions. Few studies have provided a comprehensive assessment of disease complication rates in a contemporary population of patients with JIA. The primary objective of this study was to provide a comprehensive report of disease complications in our JIA population. Secondary objectives included characterizing patients who developed complications and identifying associated risk factors.
methodsWe conducted a prospective cohort study. A standardized list of JIA disease complications was created by consensus among rheumatologists and included in the electronic medical record. A total of 432 patients diagnosed with JIA for more than one year were evaluated at our rheumatology clinic between January 2023 and February 2024 and were assessed for the development of disease complications. Univariate analysis was used to test for associations between the presence of complications and potential risk factors such as sex, age of disease onset, diagnosis duration, serology positivity, and treatment history.
resultsOf the 432 patients, 146 (33.8%) were identified to have at least one disease complication. Joint complications occurred in 73 patients (16.9%), and uveitis was identified in 57 patients (13.2%), with 14 (25%) of those experiencing secondary ocular complications. Growth failure was observed in 4% of patients, with short stature resulting in 1%. Younger age at disease onset and longer time to initiation of biologic therapy were associated with an increased risk of developing complications. Additionally, delayed initial rheumatology evaluation and delayed initiation of biologic therapy were both associated with a progressively increasing risk of joint complications.
conclusionDespite therapeutic advances in the treatment of JIA, a substantial proportion of patients continue to develop disease complications. Approximately one-third of patients in our cohort experienced at least one disease complication. Delayed initiation of biologic therapy was associated with higher complication rates, highlighting the importance of early therapeutic intervention to reduce the burden of disease complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.